Bright Minds Biosciences Inc.

DRUG

CA10919W4056

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange Other stock markets 19:46:40 05/06/2024 BST			5-day change	1st Jan Change
1.48 ^CAD	-6.92%		-9.76%	-30.19%

05-16	Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
03-22	Bright Minds Biosciences Inc. announced that it expects to receive $0.05416 million in funding	CI

Bright Minds Biosciences Inc. Announces Resignation of Williamson from Board of Directors and Audit Committee

February 08, 2023 at 09:15 pm

Bright Minds Biosciences Inc. announced the resignation of Dr. Williamson from the Company's board of directors and audit committee.

Latest news about Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-16	CI
Bright Minds Biosciences Inc. announced that it expects to receive $0.05416 million in funding	03-21	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-12	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	12-29	CI
Bright Minds Biosciences Inc. announced that it has received $0.9 million in funding	12-21	CI
Bright Minds Biosciences Inc. announced that it expects to receive $0.9 million in funding	12-05	CI
Bright Minds Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	14/08/23	CI
Top Midday Gainers	08/08/23	MT
Bright Minds Biosciences on "Positive" qEEG Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	08/08/23	MT
Bright Minds Biosciences Brief: Announcing "Positive" qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101	08/08/23	MT
Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101	08/08/23	CI
Bright Minds Biosciences Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	20/07/23	MT
Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101	20/07/23	CI
Bright Minds Biosciences Brief: Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101	20/07/23	MT
Bright Minds Biosciences Brief: Will Consolidate Its Common Shares On a 5) to 1 Basis; Co's post-Consolidation Shares Expected to Begin Trading on the CSE and The NASDAQ Capital Market on July 14, 2023	11/07/23	MT
Bright Minds Biosciences Announced Proposed Share Consolidation	22/06/23	MT
Bright Minds Biosciences Brief: Announcing Proposed Share Consolidation	22/06/23	MT
Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	15/05/23	CI
Bright Minds Biosciences Receives "Favorable" Written Opinion from International Searching Authority for BMB-202	19/04/23	MT
Bright Minds Biosciences Brief: Says Received a "Favorable" Written Opinion from International Searching Authority for BMB-202	19/04/23	MT
Bright Minds Biosciences Inc. Receives Favorable Written Opinion from the International Searching Authority for BMB-202	19/04/23	CI
Bright Minds Biosciences Provides Clinical Program Updates	27/02/23	MT
Bright Minds Biosciences Brief: Providing Clinical Program Updates and Outlines Anticipated Milestones for 2023	27/02/23	MT
Bright Minds Biosciences Inc. Provides Clinical Program Updates	27/02/23	CI
Bright Minds Biosciences Inc. Announces Appointment of David Weiner as Non-Executive Director	17/02/23	CI

Chart Bright Minds Biosciences Inc.

Duration

Period

More charts

Bright Minds Biosciences Inc. is a biotechnology company. The Company is focused on developing transformative treatments for neuropsychiatric disorders, epilepsy, and pain. It has a portfolio of next generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, post-traumatic stress disorder (PTSD), and pain. Its pipeline includes BMB-101, BMB-202, and BMB-xxx. BMB-101 is for the treatment of Dravet syndrome and other neurological and neuro-psychiatric disorders. The Company has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling while avoiding off-target effects.

Sector

Biotechnology & Medical Research

Calendar

25/08/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BRIGHT MINDS BIOSCIENCES INC.	-30.19%	4.8M
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research